

Representative Legal Matters

Jane Hobson

- Astellas: Advised on various matters including (i) the acquisition of Quethera, a clinical stage gene-therapy company; and (ii) the acquisition of Nanna Therapeutics, a clinical stage UK biotech.
- Sandoz: Advised in relation to the sale of their Chinese business to Aspen in return for European rights to certain products as well as various other disposals/licensing transactions.
- Servier: Advised on the acquisition of a potential treatment for Fragile X syndrome (FXS) from the biotechnology company Kaerus Bioscience.
- CSL: Advised on its strategic collaboration and option agreement with privately held Dutch biotech company VarmX BV to develop novel treatments for blood disorders.
- GSK: Advised on the separation of GSK's global consumer healthcare business to form independently listed Haleon plc.
- Galapagos NV: Advised on the sale of its Jyseleca business to Alfasigma S.p.A.
- Lonza: Advised on its divestment of its manufacturing sites at Ploermel, France and Edinburgh, UK.
- Platinum Equity: Advised on its USD 2.1 billion acquisition of J&J's LifeScan business in over 70 countries.
- ICU Medical: Advised on its USD 2.7 billion acquisition of Smiths Group plc's Medical Division.
- GSK: Advised on the divestment of its global Cephalosporin antibiotics business to Sandoz.
- GSK: Advised on its joint venture with Pfizer's Consumer Healthcare business to create the World's largest over the counter healthcare business.
- GSK: Advised on the divestment of a vaccine manufacturing business based in China as part of a competitive auction.
- GSK: Advised on the divestment of its manufacturing site in Cork, Ireland to Thermo Fisher and in Canada to Bora Pharmaceuticals.
- Novo Nordisk: Advised in connection with its acquisition of a UK based biotechnology firm, Ziylo with a potential value of USD 800 million.
- UCB: Advised on its global disposal of the Nitrates Products business, including the manufacturing plant in Ireland.
- CSL Limited: Advised on its acquisition of the influenza vaccines business from Novartis.